Full Papers
The ovarian reserve as measured by the anti-Müllerian hormone is not diminished in patients with rheumatoid arthritis compared to the healthy population
M. Lopez-Corbeto1, S. Martínez-Mateu2, A. Pluma3, R. Ferrer4, M. López-Lasanta5, J.J. De Agustín6, M. Barceló7, A. Julià8, S. Marsal9
- Rheumatology Department, Vall d’Hebron Hospital, Barcelona, Spain. mireia.lopez@vhebron.net
- Rheumatology Research Group, Vall d’Hebron Research Institute, Barcelona, Spain.
- Rheumatology Department, Vall d’Hebron Hospital, Barcelona, Spain.
- Department of Clinical Biochemistry (Clinical Laboratories), Vall d’Hebron Hospital, Barcelona, Spain.
- Rheumatology Department, Vall d’Hebron Hospital, Barcelona, Spain.
- Rheumatology Department, Vall d’Hebron Hospital, Barcelona, Spain.
- Rheumatology Department, Vall d’Hebron Hospital, Barcelona, Spain.
- Rheumatology Department, Vall d’Hebron Hospital, Barcelona, Spain.
- Rheumatology Department, Vall d’Hebron Hospital, Barcelona, Spain.
CER13142
2021 Vol.39, N°2
PI 0337, PF 0343
Full Papers
Free to view
(click on article PDF icon to read the article)
PMID: 32896242 [PubMed]
Received: 26/01/2020
Accepted : 20/04/2020
In Press: 03/09/2020
Published: 09/04/2021
Abstract
OBJECTIVES:
Rheumatoid arthritis (RA) is the most prevalent chronic inflammatory arthritis, affecting 0.5–1% worldwide population and predominates in females. Altered fertility has been reported due to a decrease in ovarian reserve secondary to sustained inflammation. The anti-Müllerian Hormone (AMH) is currently the most reliable biomarker of ovarian reserve. However, few and contradictory studies have been reported to analyse the relationship between fertility in RA female patients and AMH. The aim of present study is to determine the AMH serum concentrations in a long-standing RA patient group and control group. We also sought to determine the correlation between AMH serum levels and disease activity measured by different parameters and the effect of biological DMARDs.
METHODS:
Serum AMH levels were measured in 60 women with long-standing RA aged 20–50 y.o. and compared to 59 healthy women. AMH was assessed by an electrochemiluminescence immunoassay method (ECLIA, Roche Diagnostics) and a large data set of clinical and molecular data was annotated. Demographic parameters, RA disease activity measured by DAS28 score and inflammatory biomarkers such as ESR, CRP, lymphocyte CD4+, CD8+, NK cells, IL-10 and IL-6 were determined. A comprehensive gynaecological self-administered questionnaire was given. Serum AMH levels were age-correlated. Differences between groups were calculated using Student’s t-test or Mann-Whitney U-test for continuous variables and Fisher’s exact test for categorical variables. Multivariate analysis was conducted by the partial correlation coefficient. Linear regression analysis was performed to study the effect of different variables on proportional AMH change. p-values <0.005 were considered significant.
RESULTS:
The median age was similar in AR and control groups (37.4±6.23 vs. 37.3±6.27 p=0.937). Mean disease duration was 8.37±5.36 years. The number of previous treatments was <3 in 71.7% of patients and ≥3 in 28.3%. Disease activity measured by DAS28 was 2.89± 1.54. The age-adjusted mean serum concentration of AMH was 1.27 ng/ml [IQR 0.42; 2.24] in RA patients and 1.31 ng/ml [IQR 0.46; 3.09] in controls (p=0.608). Neither disease activity (p=0.862), nor current or previous bDMARDs treatments (p=0.871) were associated with AMH levels. However, a negative linear correlation was observed between AMH and IL-10 levels (p=0.033).
CONCLUSIONS:
Our study shows that ovarian reserve determined by AMH serum levels is not reduced in rheumatoid arthritis patients compared with healthy controls. In our series, AMH levels were not affected by disease activity, however, a significant correlation was observed between AMH and IL-10 levels. These results support the role of cytokines profile in the female reproductive system and will focus further investigations in this critical area, mainly once biological DMARDs have been recommended in RA pregnant patients.
